We gratefully acknowledge support from
the Simons Foundation and member institutions.
Full-text links:

Download:

Current browse context:

q-bio.QM

Change to browse by:

References & Citations

Bookmark

(what is this?)
CiteULike logo BibSonomy logo Mendeley logo del.icio.us logo Digg logo Reddit logo ScienceWISE logo

Quantitative Biology > Quantitative Methods

Title: Screening and evaluation of potential clinically significant HIV drug combinations against SARS-CoV-2 virus

Authors: Draško Tomić (1), Karolj Skala (1), Attila Marcel Szasz (2), Melinda Rezeli (3), Vesna Bačić Vrca (4), Boris Pirkić (5), Jozsef Petrik (6), Vladimir Janđel (7), Marija Milković Periša (8), Branka Medved Rogina (9), Josip Mesarić (10), Davor Davidović (1), Tomislav Lipić (10) ((1) Center for Informatics and Computing, Ruđer Bošković Institute, Zagreb, Croatia, (2) Department of Bioinformatics and Cancer Center, Semmelweis University Budapest, Hungary, (3) Department of Biomedical Engineering, Lund University, Lund, Sweden, (4) Central Hospital Pharmacy, Clinical Hospital Center Dubrava, Zagreb, Croatia, (5) Surgery, Orthopedics and Ophthalmology Clinic, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia, (6) Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia, (7) Deprtment of Obstetricy, Clinical Hospital Centre Zagreb, (8) Institute of Pathology, School of Medicine University of Zagreb, Zagreb, Croatia, (9) Laboratory for Information and Signal Processing, Division of Electronics, Ruđer Bosković Institute, Zagreb, Croatia, (10) Faculty of Electrical Engineering and Computing, University of Zagreb, Zagreb, Croatia, (11) Machine Learning Lab and Knowledge Representations, Division of Electronics, Ruđer Bošković Institute, Zagreb, Croatia)
Abstract: In this study, we investigated the inhibition of SARS-CoV-2 spike glycoprotein with HIV drugs and their combinations. This glycoprotein is essential for the reproduction of the SARS-COV-2 virus, so its inhibition opens new avenues for the treatment of patients with COVID-19 disease. In doing so, we used the VINI in silico model of cancer, whose high accuracy in finding effective drugs and their combinations was confirmed in vitro by comparison with existing results from NCI-60 bases, and in vivo by comparison with existing clinical trial results. In the first step, the VINI model calculated the inhibition efficiency of SARS-CoV-2 spike glycoprotein with 44 FDA-approved antiviral drugs. Of these drugs, HIV drugs have been shown to be effective, while others mainly have shown weak or no efficiency. Subsequently, the VINI model calculated the inhibition efficiency of all possible double and triple HIV drug combinations, and among them identified ten with the highest inhibition efficiency. These ten combinations were analyzed by Medscape drug-drug interaction software and LexiComp Drug Interactions. All combinations except the combination of cobicistat_abacavir_rilpivirine appear to have serious interactions (risk rating category D) when dosage adjustments/reductions are required for possible toxicity. Finally, the VINI model compared the inhibition efficiency of cobicistat_abacivir_rilpivirine combination with cocktails and individual drugs already used or planned to be tested against SARS-CoV-2. Combination cobicistat_abacivir_rilpivirine demonstrated the highest inhibition of SARS-CoV-2 spike glycoprotein over others. Thus, this combination seems to be a promising candidate for the further in vitro testing and clinical trials.
Comments: 8 pages, 4 figures
Subjects: Quantitative Methods (q-bio.QM)
Cite as: arXiv:2007.16177 [q-bio.QM]
  (or arXiv:2007.16177v1 [q-bio.QM] for this version)

Submission history

From: Drasko Tomic Dr [view email]
[v1] Fri, 31 Jul 2020 17:05:28 GMT (841kb)

Link back to: arXiv, form interface, contact.